Startseite Kongressberichte & Archiv Archiv 2018 Lung Cancer Lung Cancer News from oral sessions

Lung Cancer News from Oral Sessions

Abstract LBA4 Plenary Session, Sun, 1:00 PM-4:00 PM

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) $ 1%: Open-label, phase 3 KEYNOTE-042 study.  First Author: Gilberto Lopes, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL

Conclusion: KEYNOTE-042 is the first study with a primary end-point of OS to demonstrate superiority of pembro over platinum-based chemo in pts with previously untreated advanced/metastatic NSCLC without sensitizing EGFR or ALK alterations and a PD-L1 TPS ≥1%. These data confirm and potentially extend the role of pembro monotherapy as a standard first-line treatment for PD-L1-expressing advanced/metastatic NSCLC. Clinical trial information: NCT02220894

Abstract LBA9000 Oral Abstract Session, Mon, 3:00 PM-6:00 PM

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. First Author: Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO

Conclusions: IMpower131 met its co-primary endpoint of INV-assessed PFS in the ITT population in Arm B vs Arm C. The safety profile of atezo + carbo + nab-pac or pac was consistent with the known risks of the individual treatment components; no new safety signals were identified. Clinical trial information: NCT02367794

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). First Author: Luis G. Paz-Ares, University Hospital 12 de October, Madrid, Spain

Conclusions: Adding pembro almost doubled the ORR of chemo for pts with untreated metastatic sq NSCLC. Pembro + chemo has a tolerable safety profile. Results from a second interim analysis may be available prior to the meeting.


Abstract 9001 Oral Abstract Session, Mon, 3:00 PM-6:00 PM

Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with ,1% tumor PD-L1 expression: Results from CheckMate 227. First Author: Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA

Conclusions: 1L nivo + chemo improved PFS vs chemo in pts with advanced NSCLC and < 1% tumor PD-L1 expression, and was well tolerated. Results are encouraging in this analysis, which includes only pts with < 1% PD-L1. CheckMate 227 Part 2 (ongoing) is evaluating nivo + chemo vs chemo irrespective of PD-L1 expression and will further inform benefit from this combination across different subgroups of NSCLC. Clinical trial information: NCT02477826